Found 240 articles
Stem Cell Therapy Market Growing at 18.2% CAGR During (2022-2028) to Reach USD 6.2 Billion | The Insight Partners
The Insight Partners published latest research report on "Stem Cell Therapy Market Size Report, Revenue, Trends, Segments, Share & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Application, End User and Geography”,
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced its financial results for the three and nine months ended September 30, 2022 and provided a business update.
According to Latest Report Study, the global autologous cell therapy market is predicted to surpass around USD 34.94 billion by 2030 with a CAGR of 18.13% from 2022 to 2030.
The global stem cells market size was surpassed at USD 11.9 billion in 2021 and is expected to hit around USD 31.88 billion by 2030, growing at a CAGR of 11.57% from 2022 to 2030.
According to Nova one advisor, the global Stem Cells market gathered revenue around USD 12.53 billion in 2021 and market is set to grow USD 29.68 billion by the end of 2030 and is estimated to expand at a modest CAGR of 12.4% during the prediction period 2022 to 2030.
According to Nova one advisor, the global Stem Cell Therapy market size was estimated at USD 9.87 billion in 2021 and is expected to surpass around USD 31.41 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 13.73% during the forecast period 2022 to 2030.
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022.
Caladrius Biosciences, Inc., announced that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals.
The global Stem Cells market size is expected to be worth around US$ 28.4 billion by 2030, according to a new report by Vision Research Reports.
The global Stem Cell Therapy Market is expected to reach USD 3,693.6 Million by 2027, according to a new report by Emergen Research.
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd.(“Roche”) to evaluate Cend’s lead investigational drug, CEND-1.
Autologous Cell Therapy Market is Driven by Rise in Prevalence of Neurological Disorders & Cancer and Others
Wilmington, Delaware, United States, Transparency Market Research Inc. – Transparency Market Research has published a new report titled, ‘Autologous cell therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, reported financial results for the three and six months ended June 30, 2022 and provided a business update.
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseTop-line data from all subjects expected by the first quarter of 2023
Caladrius Biosciences, Inc. announced today the completion of enrollment and dosing in its Phase 1b, open-label, proof-of-concept study of CLBS201, a CD34+ regenerative cell therapy investigational product for intra-renal artery administration, for the treatment of diabetic kidney disease.
Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
Caladrius Biosciences, Inc. today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT).
Stem Cell and Regenerative Therapy Market: Rise in Prevalence of Different Chronic Diseases across the World to Drive the Market
Wilmington, Delaware, United States, Transparency Market Research Inc.: Stem cells are body’s raw materials or cells from which all other cells with specialized functions are generated.
Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology
Cend Therapeutics, Inc. today announced that The Lancet Gastroenterology and Hepatology published data from the Phase 1b study of CEND-1.
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that The Lancet Gastroenterology and Hepatology has published data from the Phase 1b study of CEND-1.
Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group
Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma.
Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announces that its merger partner in the creation of Lisata Therapeutics (“Lisata”), Cend Therapeutics, Inc. (“Cend”) today indicated that the first patient has been treated in the Phase 2b study of CEND-1 in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma.